Cargando…

Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy

Tumor-specific T cells are frequently exhausted by chronic antigenic stimulation. We here report on a human antigen-specific ex vivo model to explore new therapeutic options for T cell immunotherapies. T cells generated with this model resemble tumor-infiltrating exhausted T cells on a phenotypic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Trefny, Marcel P., Kirchhammer, Nicole, Auf der Maur, Priska, Natoli, Marina, Schmid, Dominic, Germann, Markus, Fernandez Rodriguez, Laura, Herzig, Petra, Lötscher, Jonas, Akrami, Maryam, Stinchcombe, Jane C., Stanczak, Michal A., Zingg, Andreas, Buchi, Melanie, Roux, Julien, Marone, Romina, Don, Leyla, Lardinois, Didier, Wiese, Mark, Jeker, Lukas T., Bentires-Alj, Mohamed, Rossy, Jérémie, Thommen, Daniela S., Griffiths, Gillian M., Läubli, Heinz, Hess, Christoph, Zippelius, Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895440/
https://www.ncbi.nlm.nih.gov/pubmed/36732507
http://dx.doi.org/10.1038/s41467-022-35583-w
Descripción
Sumario:Tumor-specific T cells are frequently exhausted by chronic antigenic stimulation. We here report on a human antigen-specific ex vivo model to explore new therapeutic options for T cell immunotherapies. T cells generated with this model resemble tumor-infiltrating exhausted T cells on a phenotypic and transcriptional level. Using a targeted pooled CRISPR-Cas9 screen and individual gene knockout validation experiments, we uncover sorting nexin-9 (SNX9) as a mediator of T cell exhaustion. Upon TCR/CD28 stimulation, deletion of SNX9 in CD8 T cells decreases PLCγ1, Ca(2+), and NFATc2-mediated T cell signaling and reduces expression of NR4A1/3 and TOX. SNX9 knockout enhances memory differentiation and IFNγ secretion of adoptively transferred T cells and results in improved anti-tumor efficacy of human chimeric antigen receptor T cells in vivo. Our findings highlight that targeting SNX9 is a strategy to prevent T cell exhaustion and enhance anti-tumor immunity.